Spots Global Cancer Trial Database for philadelphia chromosome positive
Every month we try and update this database with for philadelphia chromosome positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | NCT03241940 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... | 1 Year - 30 Years | Stanford University | |
| Nilotinib, for Patients With CML-CP or CML-AP | NCT04518644 | Chronic Myeloge... | Nilotinib | 18 Years - 99 Years | Novartis | |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | NCT01190930 | Acute Lymphobla... Adult B Lymphob... Ann Arbor Stage... Ann Arbor Stage... Childhood B Acu... Childhood B Acu... Childhood B Lym... Down Syndrome Hypodiploid B A... Philadelphia Ch... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Quality-of-Life... Questionnaire A... Thioguanine Vincristine Sul... | 1 Year - 30 Years | Children's Oncology Group | |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | NCT03263572 | Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22) | Blinatumomab Cytarabine Methotrexate Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | NCT00038649 | Myelogenous Leu... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | NCT02997761 | Adult B Acute L... Philadelphia Ch... | Blinatumomab Ibrutinib | 18 Years - | University of California, Davis | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | NCT00390793 | Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... t(9;22) | Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Methotrexate Prednisone Vincristine | 18 Years - | M.D. Anderson Cancer Center | |
| Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | NCT00038649 | Myelogenous Leu... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | NCT03241940 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... | 1 Year - 30 Years | Stanford University | |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | NCT03698552 | Blasts 5 Percen... CD22 Positive Philadelphia Ch... Recurrent B Acu... Refractory B Ac... | ADCT-602 | 18 Years - | M.D. Anderson Cancer Center | |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | NCT03263572 | Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22) | Blinatumomab Cytarabine Methotrexate Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Nilotinib, for Patients With CML-CP or CML-AP | NCT04518644 | Chronic Myeloge... | Nilotinib | 18 Years - 99 Years | Novartis | |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | NCT03576547 | Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22) | Dexamethasone Ponatinib Hydro... Rituximab Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations | NCT01131325 | CML Philadelphia Ch... Chronic Myeloge... | nilotinib | 18 Years - | Novartis | |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | NCT03576547 | Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22) | Dexamethasone Ponatinib Hydro... Rituximab Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT01274351 | Chronic Myeloge... | Nilotinib | 18 Years - | Novartis | |
| Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | NCT03512405 | CD19 Positive Philadelphia Ch... Recurrent Acute... Refractory Acut... | Blinatumomab Laboratory Biom... Pembrolizumab | 18 Years - | City of Hope Medical Center | |
| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | NCT05007873 | Chronic Phase C... Philadelphia Ch... BCR-ABL1 Positi... BCR-ABL1 Positi... | Dasatinib Decitabine and ... | - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | NCT02997761 | Adult B Acute L... Philadelphia Ch... | Blinatumomab Ibrutinib | 18 Years - | University of California, Davis | |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | NCT03233854 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... NKTR-255 | 18 Years - | Stanford University | |
| Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | NCT00390793 | Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... t(9;22) | Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Methotrexate Prednisone Vincristine | 18 Years - | M.D. Anderson Cancer Center | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | NCT01424982 | Accelerated Pha... Acute Lymphobla... Adult Acute Lym... B Acute Lymphob... Blast Phase Chr... Philadelphia Ch... Untreated Adult... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Doxorubicin Hyd... Laboratory Biom... Methotrexate Ponatinib Ponatinib Hydro... Prednisone Rituximab Vincristine Vincristine Sul... | 18 Years - | M.D. Anderson Cancer Center | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
